# A Novel Microfluidic Platform for Circulating Tumor Cell Identification in Non-Small-Cell Lung Cancer

## TL;DR

A new microfluidic platform efficiently captures and identifies circulating tumor cells in lung cancer patients, supporting personalized treatment.

## Contribution

The study introduces an acoustic microfluidic platform that preserves cell viability while capturing CTCs and integrates EGFR mutation analysis.

## Key findings

- Acoustic microfluidic technology effectively captures CTCs without affecting cell viability or proliferation.
- EGFR mutation analysis on captured CTCs successfully identified mutation types in four patient samples.
- The platform provides a basis for personalized targeted therapy in lung cancer diagnosis and treatment.

## Abstract

Circulating tumor cells (CTCs) are crucial biomarkers for lung cancer metastasis and recurrence, garnering significant clinical attention. Despite this, efficient and cost-effective detection methods remain scarce. Consequently, there is an urgent demand for the development of highly sensitive CTC detection technologies to enhance lung cancer diagnosis and treatment. This study utilized microspheres and A549 cells to model CTCs, assessing the impact of acoustic field forces on cell viability and proliferation and confirming capture efficiency. Subsequently, CTCs from the peripheral blood of patients with lung cancer were captured and identified using fluorescence in situ hybridization, and the results were compared to the immunomagnetic bead method to evaluate the differences between the techniques. Finally, epidermal growth factor receptor (EGFR) mutation analysis was conducted on CTC-positive samples. The findings showed that acoustic microfluidic technology effectively captures microspheres, A549 cells, and CTCs without compromising cell viability or proliferation. Moreover, EGFR mutation analysis successfully identified mutation types in four samples, establishing a basis for personalized targeted therapy. In conclusion, acoustic microfluidic technology preserves cell viability while efficiently capturing CTCs. When integrated with EGFR mutation analysis, it provides robust support for the precise diagnosis and treatment of lung cancer as well as personalized drug therapy.